Ken Griffin Immatics N.V. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immatics N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 142,000 shares of IMTX stock, worth $769,640. This represents 0.0% of its overall portfolio holdings.

Number of Shares

142,000

Previous 169,200 16.08%

Holding current value

$769,640

Previous $1.2 Million 46.8%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$4.18 - $7.42 $170,941 - $303,440	-40,895 Reduced 12.44%	287,870 $1.3 Million
Q4 2024 Feb 14, 2025	SELL	$6.73 - $11.21 $10.7 Million - $17.8 Million	-1,592,078 Reduced 82.88%	328,765 $2.34 Million
Q3 2024 Nov 14, 2024	BUY	$10.93 - $12.92 $11.3 Million - $13.4 Million	1,035,436 Added 116.94%	1,920,843 $21.9 Million
Q2 2024 Aug 14, 2024	BUY	$9.78 - $13.49 $1.8 Million - $2.48 Million	183,920 Added 26.22%	885,407 $10.3 Million
Q1 2024 May 15, 2024	SELL	$10.23 - $12.94 $746,002 - $943,623	-72,923 Reduced 9.42%	701,487 $7.37 Million
Q4 2023 Feb 14, 2024	BUY	$7.36 - $10.89 $2.91 Million - $4.31 Million	395,902 Added 104.6%	774,410 $8.15 Million
Q3 2023 Nov 14, 2023	BUY	$11.01 - $12.62 $966,138 - $1.11 Million	87,751 Added 30.18%	378,508 $4.38 Million
Q2 2023 Aug 14, 2023	BUY	$5.92 - $12.72 $1.72 Million - $3.7 Million	290,757 New	290,757 $3.36 Million
Q4 2022 Feb 14, 2023	SELL	$8.05 - $11.58 $115,581 - $166,265	-14,358 Reduced 35.95%	25,579 $222,000
Q3 2022 Nov 14, 2022	SELL	$3.31 - $13.06 $47,538 - $187,567	-14,362 Reduced 26.45%	39,937 $399,000

Others Institutions Holding IMTX

# of Institutions

Shares Held

91.5M

Call Options Held

201K

Put Options Held

109K

View Full List

About Immatics N.V.

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $413M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

More about IMTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account